BIOR — Biora Therapeutics Share Price
0.000.00%
Last trade - 00:00- $23.68m
- $58.12m
- $0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 44.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -12686.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 143.99 | 0.16 | 1.25 | 0.3 | 0 | 0.52 | 5 | -87.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Directors
- Aditya Mohanty CEO (54)
- Eric D'esparbes CFO (53)
- Damon Silvestry COO (53)
- George Gianakopoulos SVP (59)
- Troy Seelye CIO (57)
- Matthew Cooper CSO (48)
- Hutan Hashemi CCO (42)
- Clarke Neumann GCN (57)
- Sami Shihabi OTH (49)
- Jeffrey Alter LED (58)
- Jill Howe DRC (45)
- Surbhi Sarna DRC (35)
- Jeffrey Ferrell IND (47)
- Brian Kotzin IND (72)
- Lynne Powell IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 9th, 2012
- Public Since
- June 19th, 2020
- No. of Shareholders
- 50
- No. of Employees
- 58
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 35,883,843
- Address
- 4330 La Jolla Village Drive, Suite 200, SAN DIEGO, 92122
- Web
- https://www.bioratherapeutics.com/
- Phone
- +1 7604941555
- Contact
- Chuck Padala
- Auditors
- KPMG LLP
Upcoming Events for BIOR
Q3 2024 Biora Therapeutics Inc Earnings Release
Similar to BIOR
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Biora Therapeutics share price?
As of Today at 19:38 UTC, shares in Biora Therapeutics are trading at $0.68. This share price information is delayed by 15 minutes.
How has the Biora Therapeutics share price performed this year?
Shares in Biora Therapeutics last closed at $0.68 and the price had moved by -82.56% over the past 365 days. In terms of relative price strength the Biora Therapeutics share price has underperformed the S&P500 Index by -86.13% over the past year.
What are the analyst and broker recommendations for Biora Therapeutics?
The overall consensus recommendation for Biora Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biora Therapeutics dividend yield?
Biora Therapeutics does not currently pay a dividend.
Does Biora Therapeutics pay a dividend?
Biora Therapeutics does not currently pay a dividend.
When does Biora Therapeutics next pay dividends?
Biora Therapeutics does not currently pay a dividend.
How do I buy Biora Therapeutics shares?
To buy shares in Biora Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biora Therapeutics?
As of the previous close price of $0.68, shares in Biora Therapeutics had a market capitalisation of $24.40m.
Where are Biora Therapeutics shares listed?
Here are the trading details for Biora Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BIOR
What kind of share is Biora Therapeutics?
Based on an overall assessment of its quality, value and momentum Biora Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biora Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Biora Therapeutics is $10.30. That is 1414.71% above the last closing price of $0.68.
Analysts covering Biora Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.64 for the next financial year.
What is the trend in the Biora Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biora Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -53.58%.
As of the last closing price of $0.68, shares in Biora Therapeutics were trading -45.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biora Therapeutics PE Ratio?
The Biora Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biora Therapeutics?
Biora Therapeutics' management team is headed by:
- Aditya Mohanty - CEO
- Eric D'esparbes - CFO
- Damon Silvestry - COO
- George Gianakopoulos - SVP
- Troy Seelye - CIO
- Matthew Cooper - CSO
- Hutan Hashemi - CCO
- Clarke Neumann - GCN
- Sami Shihabi - OTH
- Jeffrey Alter - LED
- Jill Howe - DRC
- Surbhi Sarna - DRC
- Jeffrey Ferrell - IND
- Brian Kotzin - IND
- Lynne Powell - IND